C4 Therapeutics, Inc.

C4 Therapeutics is headquartered in Watertown, Massachusetts and operates as a U.S.-based clinical-stage biotech company. Its reported revenue comes from collaboration agreements, which are typically global in nature because partners such as Merck KGaA, Roche, Biogen, and Betta Pharma operate internationally. The company also notes reliance on foreign or foreign-owned vendors for clinical trial materials and services, which creates supply-chain and regulatory exposure beyond the United States. Because it has no commercial product sales yet, geography matters more through where R&D is conducted, where partners are located, and where clinical and manufacturing vendors are sourced. The company has not disclosed a country-by-country revenue split in the provided excerpts.

C4 Therapeutics faces the classic risks of a clinical-stage biotech: it has no approved products, no product revenue, and expects losses for years, so financing needs remain high. Clinical development risk is central because cemsidomide, CFT8919, and other programs may fail to show sufficient safety or efficacy, or may be delayed by trial execution issues. The company also depends on third-party CROs, clinical sites, and foreign or foreign-owned vendors, which creates operational, regulatory, and supply-chain risk that could slow development or increase costs. Collaboration revenue is inherently uncertain because milestone timing and partner priorities can change, and termination or reduced activity can quickly affect reported revenue. Broader industry risks include reimbursement uncertainty, regulatory review risk, intellectual property challenges, and the possibility that targeted protein degradation does not translate into commercially successful medicines.